Anxiety/ Depression
β-Caryophyllene (BCP) is a natural sesquiterpene that has garnered attention for its potential therapeutic effects on anxiety, depression, and psychosis. Its mechanism of action primarily involves the activation of the cannabinoid receptor type 2 (CB2), which plays a crucial role in modulating stress responses and neuroinflammation.
Mechanism of Action
BCP acts as a selective agonist of the CB2 receptor, which is implicated in the regulation of neurotransmitter systems associated with anxiety and mood disorders. Preclinical studies have demonstrated that BCP effectively mitigates stress-induced behavioral changes, suggesting its potential as a treatment for anxiety and depression. Notably, the administration of the CB2 receptor antagonist AM630 completely negated the anxiolytic and antidepressant effects of BCP, underscoring the importance of CB2 receptor activation in mediating these effects.
Numerous preclinical studies have established the efficacy of BCP in various animal models:
- Behavioral Changes: BCP has been shown to induce significant behavioral modifications relevant to anxiety and depression in murine models (PMID: 24930711).
- Stress-Induced Depression: Research indicates that BCP exhibits antidepressant-like effects in models of restraint stress (PMID: 31862467).
- Neuropathic Pain and Depression: BCP has been reported to alleviate neuropathic pain and depressive-like behaviors in diabetic mice (PMID: 30864870).
Neuropharmacological Interactions
The anxiolytic and antidepressant properties of BCP may involve interactions with benzodiazepine/GABAergic receptors and the inhibition of nitric oxide synthesis. Notably, the administration of L-arginine significantly reversed the anxiolytic, antidepressant, and anticonvulsant activities of BCP, indicating a complex interplay between these systems (PMID: 32386503).
Sleep and Coordination Effects
BCP has been observed to decrease latency to sleep and increase total sleep duration, exhibiting anxiolytic-like effects without impairing motor coordination. These effects appear to be independent of 5-HT1A and benzodiazepine receptors, likely involving CB2 signaling pathways that regulate emotional behaviors (PMID: 22542869).
Implications for Schizophrenia and CNS Disorders
The activation of CB2 receptors has been linked to the regulation of cognitive functions and mood-related behaviors, which are often disrupted in schizophrenia. BCP's potential to ameliorate symptoms associated with psychosis and mood disturbances positions it as a promising candidate for further investigation in the treatment of central nervous system (CNS) disorders. Studies have shown that CB2 receptor agonism can reverse MK-801-induced disruptions in pre-pulse inhibition, a model for assessing cognitive deficits (doi: 10.1007/s00213-014-3481-x).
Conclusion
In summary, β-caryophyllene demonstrates significant potential as a therapeutic agent for anxiety, depression, and psychosis through its selective activation of CB2 receptors. While preclinical evidence supports its efficacy, further clinical trials in human populations are necessary to validate these findings and explore its therapeutic applications in psychiatric disorders. The exploration of CB2 receptors as a target for CNS disorders may pave the way for novel treatment strategies in managing mood-related disturbances and cognitive impairments associated with schizophrenia and other psychiatric conditions.
Testimonial from health care worker: With all that has happened I find myself completely grief- stricken, an enormous emptiness I have never felt in my entire life. My life has been hellacious to say the least! But tonight I was in extreme pain, fatigued and inflamed. I used a full dropper of the BCPLUS within 20 minutes it alleviated my issues! The release of depression was almost immediate as well as the ache and stiffness which is subsiding. Totally miraculous! The black cloud upon me is lifting.”
Recommendation: BCPLUS liposomal 1/2 to 1mL twice or three times per day with or without food. Sleep is characteristically enhanced.
References
1. PMID: 24930711 - β-Caryophyllene, a CB2 receptor agonist, produces multiple behavioral changes relevant to anxiety and depression in mice. (2014)
2. PMID: 31862467 - Antidepressant-like effects of β-caryophyllene on restraint plus stress-induced depression. (2020)
3. PMID: 30864870 - Caryophyllene, a natural sesquiterpene, attenuates neuropathic pain and depressive-like behavior in experimental diabetic mice. (2014)
4. PMID: 32386503 - Anticonvulsant, anxiolytic, and antidepressant properties of caryophyllene: Involvement of benzodiazepine-GABAergic, serotonergic, and nitrergic systems. (2020)
5. PMID: 22542869 - β-Caryophyllene decreases the latency and increases sleep time, showing anxiolytic-like effects without altering motor coordination. (2012)
6. doi: 10.1016/j.pnpbp.2012.04.012 - The anxiolytic-like effect of an essential oil derived from Spiranthera odoratissima A. St. Hil. leaves and its major component, β-caryophyllene, in male mice. (2012)
7. doi: 10.1007/s00213-014-3481-x - CB2 receptor agonism reverses MK-801-induced disruptions of prepulse inhibition in mice.
8. doi: 10.1016/j.neubiorev.2020.04.020 - Contribution of CB2 receptors in schizophrenia-related symptoms in various animal models: Short review.
These references provide a comprehensive basis for the claims made regarding the effects of β-caryophyllene on anxiety, depression, and psychosis.
•• Detailed Clinical consultation: https://goo.gl/XTqhxR
•• Disclaimer: BCP is not approved for use as a treatment of any medical condition. This information is based on animal studies because few human trials have not been done. My recommendations are mere suggestions for dietary supplementation to be considered under direction of your health care provider advice.
Disclaimer: BCP is not approved for use as a treatment of any medical condition.
Mechanism of Action
BCP acts as a selective agonist of the CB2 receptor, which is implicated in the regulation of neurotransmitter systems associated with anxiety and mood disorders. Preclinical studies have demonstrated that BCP effectively mitigates stress-induced behavioral changes, suggesting its potential as a treatment for anxiety and depression. Notably, the administration of the CB2 receptor antagonist AM630 completely negated the anxiolytic and antidepressant effects of BCP, underscoring the importance of CB2 receptor activation in mediating these effects.
Numerous preclinical studies have established the efficacy of BCP in various animal models:
- Behavioral Changes: BCP has been shown to induce significant behavioral modifications relevant to anxiety and depression in murine models (PMID: 24930711).
- Stress-Induced Depression: Research indicates that BCP exhibits antidepressant-like effects in models of restraint stress (PMID: 31862467).
- Neuropathic Pain and Depression: BCP has been reported to alleviate neuropathic pain and depressive-like behaviors in diabetic mice (PMID: 30864870).
Neuropharmacological Interactions
The anxiolytic and antidepressant properties of BCP may involve interactions with benzodiazepine/GABAergic receptors and the inhibition of nitric oxide synthesis. Notably, the administration of L-arginine significantly reversed the anxiolytic, antidepressant, and anticonvulsant activities of BCP, indicating a complex interplay between these systems (PMID: 32386503).
Sleep and Coordination Effects
BCP has been observed to decrease latency to sleep and increase total sleep duration, exhibiting anxiolytic-like effects without impairing motor coordination. These effects appear to be independent of 5-HT1A and benzodiazepine receptors, likely involving CB2 signaling pathways that regulate emotional behaviors (PMID: 22542869).
Implications for Schizophrenia and CNS Disorders
The activation of CB2 receptors has been linked to the regulation of cognitive functions and mood-related behaviors, which are often disrupted in schizophrenia. BCP's potential to ameliorate symptoms associated with psychosis and mood disturbances positions it as a promising candidate for further investigation in the treatment of central nervous system (CNS) disorders. Studies have shown that CB2 receptor agonism can reverse MK-801-induced disruptions in pre-pulse inhibition, a model for assessing cognitive deficits (doi: 10.1007/s00213-014-3481-x).
Conclusion
In summary, β-caryophyllene demonstrates significant potential as a therapeutic agent for anxiety, depression, and psychosis through its selective activation of CB2 receptors. While preclinical evidence supports its efficacy, further clinical trials in human populations are necessary to validate these findings and explore its therapeutic applications in psychiatric disorders. The exploration of CB2 receptors as a target for CNS disorders may pave the way for novel treatment strategies in managing mood-related disturbances and cognitive impairments associated with schizophrenia and other psychiatric conditions.
Testimonial from health care worker: With all that has happened I find myself completely grief- stricken, an enormous emptiness I have never felt in my entire life. My life has been hellacious to say the least! But tonight I was in extreme pain, fatigued and inflamed. I used a full dropper of the BCPLUS within 20 minutes it alleviated my issues! The release of depression was almost immediate as well as the ache and stiffness which is subsiding. Totally miraculous! The black cloud upon me is lifting.”
Recommendation: BCPLUS liposomal 1/2 to 1mL twice or three times per day with or without food. Sleep is characteristically enhanced.
References
1. PMID: 24930711 - β-Caryophyllene, a CB2 receptor agonist, produces multiple behavioral changes relevant to anxiety and depression in mice. (2014)
2. PMID: 31862467 - Antidepressant-like effects of β-caryophyllene on restraint plus stress-induced depression. (2020)
3. PMID: 30864870 - Caryophyllene, a natural sesquiterpene, attenuates neuropathic pain and depressive-like behavior in experimental diabetic mice. (2014)
4. PMID: 32386503 - Anticonvulsant, anxiolytic, and antidepressant properties of caryophyllene: Involvement of benzodiazepine-GABAergic, serotonergic, and nitrergic systems. (2020)
5. PMID: 22542869 - β-Caryophyllene decreases the latency and increases sleep time, showing anxiolytic-like effects without altering motor coordination. (2012)
6. doi: 10.1016/j.pnpbp.2012.04.012 - The anxiolytic-like effect of an essential oil derived from Spiranthera odoratissima A. St. Hil. leaves and its major component, β-caryophyllene, in male mice. (2012)
7. doi: 10.1007/s00213-014-3481-x - CB2 receptor agonism reverses MK-801-induced disruptions of prepulse inhibition in mice.
8. doi: 10.1016/j.neubiorev.2020.04.020 - Contribution of CB2 receptors in schizophrenia-related symptoms in various animal models: Short review.
These references provide a comprehensive basis for the claims made regarding the effects of β-caryophyllene on anxiety, depression, and psychosis.
•• Detailed Clinical consultation: https://goo.gl/XTqhxR
•• Disclaimer: BCP is not approved for use as a treatment of any medical condition. This information is based on animal studies because few human trials have not been done. My recommendations are mere suggestions for dietary supplementation to be considered under direction of your health care provider advice.
Disclaimer: BCP is not approved for use as a treatment of any medical condition.